Durvalumab and Tremelimumab with Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma

Trial Identifier: D419CL00025
Sponsor: AstraZeneca
Start Date: August 2025
Primary Completion Date: November 2026
Study Completion Date: December 2028
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100044
CN Beijing, CN, 100029
CN Beijing, CN, 100142
CN Chengdu, CN, 610078
CN Chongqing, CN, 400016
CN Guangzhou, CN, 510515
CN Guangzhou, CN, 510060
CN Guangzhou, CN, 510120
CN Guangzhou, CN, 510095
CN Hangzhou, CN, 310022
CN Hefei, CN, 230022
CN Jinan, CN, 250021
CN Nanjing, CN, 210029
CN Nanjing, CN, 210009
CN Ningbo, CN, 315010
CN Shanghai, CN, 200438
CN Taiyuan, CN, 030001
CN Tianjin, CN, 300060
CN Wenzhou, CN, 325000
CN Wuhan, CN, 430030
CN Xiamen, CN, 361004
CN Zhengzhou, CN, 450052